Abstract Nanobodies (Nbs) have arisen as an alternative to conventional antibodies (Abs) and show great potential when used as tools in different biotechnology fields such as diagnostics and therapy. Different approaches have been described for the production of Nbs and these methods face new challenges focused on improving yield, affinity, and reducing production costs. This review summarizes these challenges, and also the latest advances in the detection of different kinds of molecules, such as proteins and small molecules, and describes their potential use for noninvasive in vivo imaging and for in vitro assays. Moreover, the unique properties of Nbs are outlined like internalization, size, thermal and chemical stability, affinity, blood clearance, and labeling procedures. Concerning therapeutic applications, we highlight some already reported examples about Nbs being used for the treatment of several diseases such as cancer, neurodegenerative or infectious diseases among others. Finally, future trends, opportunities, and disadvantages are also discussed.
Introduction
Antibodies (Abs) are considered one of the best biomolecules used for detection and targeting purposes. This is due to their particular characteristics such as high affinity and high specificity that can be useful for research, diagnostics, and therapeutic applications. However, there is an increasing demand to improve some properties of the Abs that are currently being used.
A large variety of immunoassay formats have been developed to tackle different questions related to diagnostic issues: presence or absence of a specific antigen (Ag), the amount of a particular substance present in the analyzed sample, or to localize a compound in different tissues. In addition, diagnostic applications have recently focused on the development of biosensors capable of detecting a particular analyte very quickly and at the doctor's office, called point of care (PoC) devices, and as well in the field of noninvasive in vivo imaging. Abs have also been used for therapeutic applications, blocking the interaction between the target and the corresponding receptor, or disrupting the signal transduction cascade induced after their recognition [1] .
Antibodies or immunoglobulins (IgGs) are serum glycoproteins that are involved in the immune response after the presence of an external stimulus (Ag) as a defense mechanism. IgG comprises four polypeptide chains that generate the characteristic Y-shape structure (Fig. 1) . From this general structure several fragments can be identified such as the antigenbinding fragment (Fab) and the single chain variable fragment (scFv) which contains the biorecognition area but lacks the constant fraction.
Single domain Abs or commonly named nanobodies (Nbs) have been found as an alternative to conventional Abs given their improved features [2, 3] . Nbs are produced mainly in camelids such as llamas, alpacas, or camels. These host animals have the ability to produce immunoglobulins which only contain the heavy chain (HCAb) and completely lack the light chain. The heavy chain is structured into two constant regions (CH2 and CH3), a long hinge region, and the Ag-binding domain VHH [4] . Specifically, VHH is formed from different regions, ones that are more conserved (FR) and others that are responsible for the specific recognition of the Ag, called complementary determining regions (CDRs) [5] , the one called CDR3 being the region that shows best degree of recognition [6] . Hence, Nbs are Ab fragments that have been produced by recombinant technology raising a VHH region (Fig. 1) .
Nanobodies are good candidates to improve the physicochemical properties of conventional monoclonal Abs (mAbs) and maintain the degree of recognition, which is stated to be in the nanomolar range [7] . The main advantages of Nbs and how their properties can be tailored to different fields of interest are widely described in the literature (Fig. 2) . In this sense, one of the main advantages of obtaining Nbs by recombinant technology is that several tags can be fused in their tertiary structure such as His-tag or even fluorescent labels like the green fluorescent protein (GFP) [8] . Also, Nbs can be produced on a large scale with good yields. The lack of light chain in their structure provides them with low immunogenicity, better stability in terms of thermal resistance, unfolding reversibility, proteolytic resistance, and high solubility [9, 10] . Nbs are smaller (15 kDa) than conventional IgGs (150 kDa) or their corresponding Fab fragments (55 kDa) or scFv (28 kDa) which can be prepared chemically or by recombinant methodologies. The lower stability of those fragments may be the reason for the lower affinity when compared with the corresponding IgG. This fact can be overcome by Nbs owing to their higher stability and ability to keep affinity parameters in the nanomolar range [11] .
The current application areas in which Nbs have been used are mainly related to diagnostics and therapeutic purposes [3, 12, 13] , although they have also been applied for research on biochemical mechanisms as well as for structural biology studies. Concerning diagnostics, Nbs have been reported as useful tools for applications in vitro (diagnostics kits) and in vivo (for instance for imaging purposes, mainly by adding different labels that will help with their monitoring). On the other hand, targeting Ag specificity is a very convenient property for their therapeutic applications; for example, Nbs are potential candidates to treat different diseases such as cancer and also show the ability to cross the blood-brain barrier [6] .
Nanobody production
One of the main challenges of Nb production is the selection and identification of the best technology for their preparation. Obtaining libraries that contain the required genetic information is critical to produce Nbs with high specificity and affinity properties. Ag-specific Nbs can be produced through immune, naïve, or synthetic libraries [7] .
Immune libraries are the most common option for the production of Nbs. They require an active immunization of Camelidae animals such as camels, dromedaries, llamas, or alpacas. The generation of in vitro Nbs produced via antigen-induced immunization requires the extraction of mRNA from isolated lymphocytes, after a protocol of immunization [14] . Once the specific sequence is amplified and inserted in a cloning vector, the screening process to isolate the most suitable Nbs is performed by taking advantage of phage display technology, or using other methods like cell surface display, mRNA/cDNA display, or MS spectrometric identification [7] . The most commonly used strategy to carry out this sort of screening is based on phage display selection. Basically, it consists of the isolation of mRNA from the lymphocytes, subsequent amplification of the sequence encoding for the mature Nb repertoire by PCR, and then, after including restriction enzyme sites, the different fragments are inserted into a phagemid cloning vector. Later on, the VHH library is produced by infecting the phage expression system. Finally, an antigen-specific phage selection needs to be performed. After the selection of the most suitable clone, the corresponding soluble VHH is produced (Fig.3) . The selection of the most suitable phage displaying Nbs is critical. This step is usually performed using in vitro assays (i.e., phage ELISA), taking into consideration the Ag that you want to determine. Two to three rounds of panning are usually required to identify the positive phages. However, if the specificity criteria of Nb selection are higher, the number of rounds required to obtain a customized Nb could increase. Subsequently to the selection, the production of the corresponding Nbs will be performed in vitro by using an expression system. The main advantages that these kinds of libraries present reside in the fact that the expected specificity is determined by the antigenicity of the Ag. In addition, compared with the conventional polyclonal and monoclonal Abs, the generation of Nbs obtained by phage display technology is relatively fast to produce and has low cost.
Nb selection from naïve libraries takes advantage of the natural immunological diversity of the host animal per se, without immunization [2, 12] . Therefore, a large amount of blood is required to increase the genetic diversity. Clearly, this strategy is the most appropriate one when looking for specific Nbs recognizing low immunogenic targets. In addition, this is a less directed method than the previous one but more universal, allowing the production of Nbs from less antigenic compounds. In any case, the success of this process depends on the amount of blood samples collected and it should be taken into account that only high specificity Abs can be obtained.
Other strategies relying on the use of semisynthetic/ synthetic libraries are based mainly on keeping the common conserved structure of the Nbs and randomly varying the corresponding CDR sequences. The degree of diversity that can be induced by preparing these types of libraries is higher than when the protocol performed depends on naïve libraries. This is due to their capability to introduce different amino acids in the selected CDR regions. Hence, these sorts of libraries are considered a promising alternative to the conventional method including immunization of animals.
Concerning Nb production, a wide range of different expression models can be used including organisms such as bacteria, yeast, fungi, insect cells, mammalian cells, or even plant hosts [15] . The most widely used expression system is Escherichia coli, which expresses proteins in different cellular compartments. The main advantage of working with this expression host is that it enables the production of soluble functional Nbs and that requires cheap protocols. Conversely, the yields are not very high compared with organisms such as yeast or fungi. Another usual way to produce Nbs uses mammalian cells. This is the most suitable choice when Nbs are produced for therapeutic purposes, although their cost, long time requirements, and complex handling do not make them the first option. Other possible methods include the use of yeast and fungi, which have already been successfully applied, but the production process is still complex.
Moreover, the fact that Nbs can be expressed in different organisms is an advantage with respect to conventional monoclonal Ab production since it allows insertion of customized tags, production at low cost, and high production scale. 
Unique features of nanobodies
Nbs show some striking advantages versus conventional Abs that are noteworthy since they combine desirable features of mAbs with some of the beneficial properties of small molecule drugs.
& They can bind a broad range of epitopes showing affinities in the nanomolar or even picomolar range. This implies that the affinities of Nbs are comparable or superior to those of conventional mAbs, reaching picomolar affinity constant range [16, 17] . They have evolved to show high specificity and affinity by just presenting three CDRs instead of six occurring in conventional Abs [17] . Crystallographic studies have reported [18] that Nb antigen-binding loops display a larger structural repertoire. In addition, CDR3 regions are usually longer than the VH domains of mAbs. & Possibility of formatting or multimerization. Given the small size and their monomeric nature of Nbs, they can be genetically engineered to obtain modular blocks that can be fused to form a new construct which will enable multispecificity and versatility. For therapeutic purposes, bivalent and bispecific Nbs are a very attractive format. Bivalency allows Abs to bind to multimeric Ags with great avidity [19] , and bispecificity consists of simultaneously binding to two different types of Ag [20, 21] . These types of immunoreagents can be produced by molecular engineering, in most cases rendering chimeric Abs. This option is particularly attractive for therapeutic applications and to extend the half-life of these immunoreagents. & They are highly stable and soluble. Nbs present optimal biophysical and biochemical properties including solubility, thermal tolerance, and proteolytic resistance. The folding of CDR3 loop and the hydrophilic content of the framework-2 region gives them high solubility in aqueous solutions and lack of aggregation [22] . In addition they impart high conformational and thermal stability. Therefore, Nbs keep full binding capacities after 1 week at 37°C [23] and thermal unfolding behavior often has been described as completely reversible after long incubation periods at 90°C [24] . Aside from thermal resistance, Nbs are stable in the presence of proteases and chaotropic agents as well as at extreme pHs [25] . Moreover, they can be customized to circumvent intracellular proteolysis. This behavior, along with their ability to modulate target activity, places them as perfect agents to impair intracellular Ag activity, generating functional knockouts. With this aim, intrabodies have been developed, which are recombinant Ab fragments or Nbs that have been intracellularly expressed to target intracellular proteins. They Nanobody production scheme using a phage display library. The genetic information can be obtained by active immunization using an immunogen or using non-immunized animals by collection of blood which contains the lymphocytes. Increasing the diversity using semisynthetic libraries and randomly introducing amino acids in the CDR region is possible in order to improve the binding capabilities.
After the insertion of the plasmid in a bacterophage, the phagemid library is ready for this selection. Phage ELISA is the usual way to perform the biopanning. After the best candidate is selected, the production of the nanobody can be expressed in bacteria, yeast, or mammalian cells through its corresponding expression vector have been very useful to fight against intracellular pathogens or to treat neurodegenerative diseases [26] . Proteolytic resistance and their stability under extreme conditions also make them suitable for use in alternative routes of administration (i.e., oral administration). Regarding the use of Nbs for diagnostic purposes, the high stability of Nbs at high organic solvent concentrations or at extremes of pH or temperatures opens a wide range of applications for the detection of small molecules [27] or proteins. This is due to the fact that these physical characteristics allow the use of more efficient immobilization methods for biosensing purposes, the possibility to anal y z e p o l l u t a n t s at l o w c on c e n t r a t i o n af t e r a preconcentration step, or even permits one to increase the kinetics of biorecognition by working at high temperatures. & Deep and fast tissue penetration and rapid blood clearance. Since passive intercellular diffusion rate within a tissue depends on the molecular size and is approximately inversely proportional to it, a 15-kDa monovalent Nb should improve the penetrability when compared with the performance of conventional mAbs (150 kDa). This feature can be very useful for targeting tumors, given that Nbs can be designed to modify or neutralize oncogenic molecules, redirecting them to a specific cellular compartment or expressing them on the tumor cell surface to trigger an immune response [28] . Since therapy usually requires high doses and frequent administration of the specific therapeutic agent, several methods have been developed to increase the half-life of HCAbs. These include the addition of polyethylene glycol [29] , conjugation to albumin, or fusion to an Fc fragment of a conventional Ab. Nevertheless it is worth mentioning that for some specific applications this rapid renal clearance that characterizes Nbs may have its advantages, avoiding toxicity effects. Moreover, great expectation has been placed in the capability of Nbs to cross the blood-brain barrier (BBB) owing to their small size [3, 6] . & Recognition of hidden epitopes. Crystallographic studies of conventional Abs have revealed that in most cases the Ag-binding surface is flat or concave [30] . Conversely, Nbs often bind into clefts and cavities (reviewed in [31] ). The lack of variable light chain (VL) is balanced with a VHH region that shows an extended CDR1 and a more exposed CDR3. These structural changes allow standard binding architectures such as planar surfaces and cavities but also include the possibility of binding protruding loops or clefts [32] . Therefore this feature of Nbs and their smaller size promote the interaction with novel epitopes that are inaccessible to conventional VH-VL pairs, and also explain the ability of Nb to bind and neutralize targets that are notoriously difficult to hit with conventional Abs.
& Immunogenicity. Camelid VHH domains present high degree of homology with human VH domains, which means that to date they have not shown any unexpected immunogenicity reactions, which can be a potential concern for clinical applications [2] . Nevertheless, and just in case of long therapeutic treatments, it is a safe option to first humanize the framework-2 region to have available an amino acid sequence showing high degree of homology compared to human VHs. The humanization [33] of Nbs can be performed by a straightforward site-directed mutagenesis given that the gene comprises only approximately 380 base pairs. & Production costs. mAbs are large multimeric proteins that usually undergo post-translational modifications. Hence, their production requires sophisticated machinery only found in eukaryotic systems. In addition, to achieve clinical efficacy in therapeutic treatments, these molecules have to be administered in large doses. The result of all of these requirements translates into the need to use very large mammalian cell cultures and long screening and purification steps, leading to very expensive production costs and limiting their manufacturing as therapeutic drugs. Nbs are a good alternative to solve the problem of mAb production costs. Nbs can be easily expressed in microbial systems (such as bacteria, yeasts, fungi) [7] and rapidly selected from display libraries since immune specificity is fully restored. Moreover, they are particularly manageable for high-throughput screenings by using sequencing technologies, for example. All of these production and selection advantages result in lower manufacturing prices.
Applications of nanobodies as diagnostic and therapeutic tools

Detection of proteins and microorganisms
Most commercial diagnostics tests are based on the detection of certain proteins related to a specific disease and the majority rely on the use of Abs. However, in certain situations where the Ab can lose its stability and biorecognition properties, Nbs can be positioned as a good alternative given their resistance and stability [34] during long periods of time once immobilized in solid supports. Recently, the development of a lateral flow assay based on the use of Nbs was reported for the determination of Trypanosoma congolense infection in plasma [35] . The detection is done through the determination of a specific biomarker that was determined after a biopanning process. The immunization was performed using a mixture of secretomes of T. congolense. The selection was made by MS identification looking at the secretome compounds bound by the produced Nbs and searching for the occurrence of a single protein band between 55 and 70 kDa. This band corresponds to the pyruvate kinase of T. congolense. Subsequently, a sandwich ELISA was developed and successfully tested in plasma. Finally, a lateral flow assay based on Nbs was also developed for determination of parasitemia with good sensitivity (79.2 ± 16.2) and specificity (91.9 ± 8.8) parameters. The LOD accomplished was 220 ng/mL and 14 ng/mL in plasma using LFA and ELISA, respectively.
The production of anti-idiotypic Nbs has been reported for the determination of a Cry1Ab toxin important for analysis of genetically modified organisms [36] . The assay developed in this case is a chemiluminescence immunoassay tested in crops. On this occasion, the selection was performed by phage display through a high-quality naïve library. Biopanning was carried out using an anti-Cry1Ab monoclonal Ab as mimetic Ag relying on the paratope recognition of the mentioned Ab. A f t e r t h e N b s e l e c t i o n p r o c e s s , a c o m p e t i t i v e chemiluminiscence assay was developed. The working range obtained was 10.49-307.1 ng/mL when directly applied in cereal samples.
Regarding the detection of bacteria, some examples can be found in the literature about Nb production performed by active immunization of the protein or biomarker of interest. However, few examples have been reported using naïve libraries. One of them was reported by Tu and coworkers [37] which produced Nbs for detecting Listeria monocytogenes in milk and developed a sandwich immunoassay with a LOD of 10 4 cfu/mL. Nbs can also be used to monitor biomolecules such as enzymes. For example, Zafra and coworkers [38] reported immunizing with a mixture of 12 purified enzymes isolated from aerobic and anaerobic microorganisms associated major types of detoxifying activities. Thus, the authors took advantage of an efficient screening by using phage display methodologies, performing a simultaneous screening with each one of the individual components of the immunized antigenic mixture. Using this method, it was possible to generate specific Nbs against each of the 12 target enzymes.
Nbs have been successfully applied for the development of biosensors. Biosensors are devices where a bioreceptor, in this case a Nb, is in close contact with a transducer that converts the biorecognition event into a measurable signal. In this context, Campuzano and coworkers [39] developed a competitive immunosensor based on the use of magnetic particles with an electrochemical readout for the determination of fibrinogen. Indirect and direct formats were both explored, immobilizing the Nb or the competitor onto the magnetic beads respectively. The results revealed similar detectability with the two formats tested, the indirect one being the better, reaching a LOD of 0.044 μg/mL.
Detection of small molecules
The production of Abs for the detection of low molecular weight compounds (<1000 Da) requires the preparation of immunizing haptens that mimic the physicochemical properties of the target analyte [40] . The preparation of haptens has been successfully achieved for a wide variety of compounds including targets related to the environment, food matrices, and biological samples. Subsequently, the production of polyclonal and monoclonal Abs with these haptens has also been accomplished. However, despite the excellent analytical features achieved, the use of these Abs has revealed the need to improve their stability against important external agents such as temperature or organic solvents for which Nbs have shown high tolerance [41, 42] .
The first attempts to produce Nbs for low molecular weight molecules were able to detect methotrexate [43] and azoxystrobin [44] in the micromolar range. The detection limit was improved to the low nanomolar range when performing Nb-based immunoassays for tetrabromobisphenol A [45] which allowed the detection of the required levels as part of a risk assessment of environmental exposure. In food safety, Nbs have been used for the determination of mycotoxins [27] and successfully applied to detect these compounds in crops. It is in these fields where the advantages of Nbs regarding their tolerance to temperature and organic solvents are quite important since they can be applied for the detection of contaminants in different environments. Thus, Wang et al. [45] and Kim et al. [46] reported the development of Nbs that resist organic solvent concentrations up to 50% for methanol and DMSO. Pan and coworkers [47] demonstrated Nb tolerance not only for the aforementioned solvents but also for acetone and ethanol. In all the cases, Nb analytical parameters were similar compared with those obtained in buffer conditions. Concerning temperature tolerance, Liu and coworkers [48] tested the stability of Nbs by preincubating them along with the sample. All Nbs assayed kept their properties intact after 5 min at 50°C and some of them could even be used after 5 min at 100°C. Additionally, they showed that Nbs were able to reach 60% of their activity after 75 min at 90°C. Similar behavior has been found regarding the robustness of the Nbs at different pH. Wang and coworkers [45] reported great stability between pH 7.4 and 10.
The detection of low molecular weight molecules generally requires setting up competitive assays either in direct or indirect format. Thus, Ab labeling is needed to visualize the binding to the corresponding target analyte. Considering that Nbs can be recombinantly expressed, the reporter label (e.g., GFP or alkaline phosphatase) can be incorporated as an insert during the cloning process, keeping intact the analytical performance of the initial Nb [49] . Another recently reported strategy consists of using idiotypic Abs as surrogate Ags that also detect the target pollutant and afforded LODs in the sub-parts per billion range [50] . In this case, these anti-idiotypic Nbs were immobilized in an immunochromatographic strip with the aim of developing a time-resolved fluorescence immunochromatographic assay for the determination of zearalenone and aflatoxin B1 (APB1).
Despite the advantages that Nbs present, they have not been used too much for the determination of small molecules. Hence, just a few examples can be found in the literature, regarding the development of immunosensors for this sort of target. In this context, another interesting example worth mentioning was reported by Pan and coworkers [47] who developed an electrochemical immunosensor for the direct determination of aflatoxin B1. Nbs were immobilized over a modified glassy carbon electrode and afforded a LOD of 3.3 pg/mL, allowing one to measure real samples. The system enabled the direct determination of APB1 without any labeling.
Thus, potential diagnostic applications for specific Nbs against small molecules are still to be exploited taking into consideration their excellent properties. Their small size, suitability for bioengineering, their high solubility, and high chemical stability allow them to overcome matrix interferences and to improve the analytical capabilities of conventional Abs.
Imaging applications
Nowadays, early diagnosis does not just involve the in vitro determination of specific biomarkers; there are other very useful applications. These include in vivo diagnosis procedures such as molecular imaging techniques which are widely used by clinicians to visualize possible disease abnormalities, mainly tumors. In this context, different methodologies are being developed that are based on nuclear imaging such as single photon emission computed tomography (SPECT) and positron emission tomography (PET) [12] . Ex vivo imaging techniques are also interesting for the evaluation of organ and tissue biodistribution. In these cases, immunofluorescence is one of the main tools that have been assessed to evaluate and localize the biomarkers of interest.
If the incorporation of radioisotopes or fluorophores into VHH is required, recombinant techniques are usually used (i.e., to add GFP) but there are also other possibilities that include mainly chemical modifications. In this context, it is worth mentioning that Nbs can be designed as chromobodies. This kind of Nbs relies on the possibility of coupling functional binding molecules such as Nbs to fluorescent proteins. This adds even more value to Nbs since they can be used for the visualization of cytoskeleton network or nuclear components [51, 52] taking advantage as well of their size. They have been demonstrated as useful tools when used as high resolution imaging probes.
When Nbs functionalization requires chemical modification, it should be performed by utilizing orthogonal functional groups to control the conjugation position of the labeling compound. These labeling molecules include fluorophores, enzymatic tracers, biotin, or different drugs [53] . Thus, given that Nbs can act as good tracers, they can be considered a good option for targeting tumors or other types of diseases such as rheumatoid arthritis.
The epidermal growth factor receptor (EGFR) is one of the best studied targets, which is directly related to different epithelial cell tumors such as skin, lung, head, and neck tumors [54] . Thus, EGFR is one of the best biomarkers used to localize tumors and it can also be radiolabeled for imaging applications or it can even be coupled to drugs for treating different kinds of cancer. To work with this target, one of the most commonly used methods consists in labeling it with the radioisotope 99m-technetium ( 99m Tc), which is widely utilized in cancer imaging. Radiolabeling of a Nb obtained against EGFR was performed using [ 99m Tc(CO) 3 (H 2 O) 3 ] + salt which has affinity for the His-tag also incorporated into the produced EGFR Nb. The bioconjugate obtained was applied for e x v i v o m e a s u r e m e n t s i n m i c e t o e v a l u a t e i t s biodistribution and for SPECT imaging, identifying EGFR overexpression.
Nbs coupled to near-infrared (NIR) dyes have also been used for cancer imaging based on targeting the HER2 tumor biomarker. Debie and coworkers [55] studied the relevance of controlling the label conjugation method to get optimal results and to improve pharmacokinetics. On the one hand, NHS-activated NIR label was coupled to the Nb randomly through free accessible lysines. On the other hand, the NIR label was specifically coupled to a carboxyl-terminal unpaired cysteine to form a disulfide bond. The affinity of carboxy-labeled NIR-Nbs was determined by measuring the dissociation constant (K D ) which was found to be around 4.5 nM; in contrast, random labeling was affected by the conjugation process (K D values ranged between 20 and 60 nM). However, the results obtained after performing in vivo and ex vivo experiments helped with more precisely identifying the HER2 overexpression using both labeled Nbs. Site specific and randomly labeled Nbs showed rapid tumor accumulation and low nonspecific uptake, resulting in high tumor to muscle ratios at early time points (respectively, 3.4 ± 1.6, and 3.5 ± 0.9 for HER2-positive tumors at 3 h postinjection (p.i.), while <1.0 for HER2-negative tumors at 3 h p.i., p < 0.05) [55] .
Thus, imaging diagnosis has been demonstrated as one of the most powerful and used applications of Nb which takes advantage of its inherent small size and subsequent rapid renal clearance. Easy functionalization with radiolabels or fluorescent probes makes Nbs ideal for in vitro and in vivo imaging. These combined properties also make Nbs ideal for disease diagnosis.
Therapeutic tools
A breakthrough in the field of therapy was achieved in 1975 by Kohler and Milstein [56] with the development of mouse hybridoma technology that allowed efficient production of monoclonal Abs (mAbs). Nowadays, different mAbs have been approved as therapeutic agents for the treatment of a broad range of indications, e.g., oncology [57] , infectious diseases [58] , transplant rejection [59] among others. Despite this noticeable success, these molecules are facing important problems when utilized as therapeutic compounds. First of all, their large size limits efficient tissue penetration (i.e., in solid tumors) and the passage through the BBB. Potentially they can exert some immunogenic effects, given their murine origin, that are only overcome by raising humanized Abs. Moreover, their production takes a long time and has elevated costs since it involves the use of cell culture techniques and tedious screening protocols.
In this context, the development of molecular biology and phage display technologies boosted the possibility of obtaining engineered and tailor-made Abs or Ab fragments which could surmount some of the limitations of mAbs explained above. The new strategies aim at the production of scaffolds of smaller size that can be easily selected and produced. Thus, Nbs seemed particularly well suited for drug development given their biophysical and biochemical characteristics.
The use of Nbs to treat diseases and pathologies mainly relies on inhibiting target-receptor interactions. On top of this, and taking advantage of the multimerization capacity of Nbs, simultaneously targeting of different pathways and/or different factors can be achieved when dealing with complex diseases. Since its discovery, Nb technology has broadened rapidly and this is proven by the increase in the number of scientific articles published lately on this subject. Thus, Nb clinical applications have been explored and reported for different fields of medicine, e.g., oncology, infectious and neurological diseases, and inflammatory pathologies among others. Some examples are reviewed here to highlight Nbs as future ideal tools for therapy, being administered as a unique treatment or in combination with other therapeutic strategies. At present there are several companies that make Nbs or Nb-derived products. All of them are at different clinical development phases, but not one is on the market or in phase IV [6] .
Abs play a key role as natural defense effectors against viral, bacterial, and parasitic infections. To battle viruses, Nbs can act at different steps of the virus replication cycle, including virus-cell attachment, viral entry, and viral uncoating. One good example is a bivalent Nb that targets H5N1 hemagglutinin thereby preventing influenza A virus attachment to the host and avoiding subsequent viral replication [60] . This is a neutralizing Nb administered intranasally in mice. Focussing on bacteria, Nbs are a very attractive alternative given the concern caused by the emergence of antibiotic resistance, the high cost of the currently available treatments, and the lack of new antibiotic development. Nbs can be raised against bacterial surface proteins, can bind bacterial motility machinery, can inhibit the type VI secretion system and prevent toxin secretion, among other strategies. A very interesting approach, since it does not involve targeting the bacteria by itself, is based on neutralizing virulence factors secreted by the pathogenic organism. This procedure could overcome antibiotic resistance given that is not based on killing bacteria. Thus, different Nbs have been developed for Clostridium difficile, a multiresistant bacteria that causes antibiotic-associated diarrhea in hospitalized patients, to block the binary CDT toxin (C. difficile transferase), an enzyme that modifies actin and induces microtubule-based cell protrusions. In this context, the production of two Nbs against CDTa and CDTb that effectively block cytotoxicity induced by the binary toxin at equimolar concentrations has already been reported [61] .
Another important application of Nb technology is focused on the therapeutic treatment of neurodegenerative diseases. This kind of illnesses is mainly caused by abnormal unfolding or aggregation of intracellular proteins (i.e., Parkinson's, Alzheimer's, and Huntington's disease). For this reason intrabodies can be considered as a good therapeutic option given their ability to cross the BBB and once inside the cell they can alter protein folding and/or interactions. In this context, inhibition of the formation of β-amyloid fibrils by using specific Nbs has been reported as a suitable strategy for treatment of Alzheimer's disease. For example, Lafaye et al. [62] obtained a Nb against amyloid β (Aβ) peptide (V31-1) that prevented Aβ-induced neurotoxicity and avoided fibril formation. This Nb was able to distinguish between different conformations of the peptide (oligomers, protofibrils, and fibrils), recognizing only oligomers and being able to prevent the formation of amyloid fibrils by stabilizing protofibrils and neutralizing the soluble fraction of oligomeric Aβ isolated in the human brain.
Finally, the Bstriking advantage^of Nbs for treating cancer resides in their specific performance, good tissue penetrability, and fast clearance. These features allow tumor penetration and at the same time avoid the damage of healthy cells. They can be used as antagonistic drugs, but the absence of an Fceffector domain reduces their efficacy but simultaneously minimizes the adverse effects. In this context, promising approaches include the use of targeting moieties bound to effector domains or even the Bdecoration^of Nbs with nanoparticles containing oncogenic drugs. Another important challenge is the development of treatments for brain cancers. In this case, the ability of Nbs to cross the BBB can be quite useful. Intrabodies are another suitable choice for redirecting antitumor triggering agents when expressed in tumor cells. Moreover, these intrabodies neutralize or modify the activity of oncogenic molecules present in specific subcellular compartments.
Other clinical applications already reported include the use of Nbs against envenoming, inflammation processes, detoxification, cytokines, and the blood clotting cascade.
Thus, in the high-throughput era, the screening for specific Nbs will become progressively a rapid and cheap standardized process. This will extend the applications of Nb to clinical diagnosis and therapeutics and to the monitoring of environmental contaminants. Moreover, their outstanding properties together with the possibility of targeting different molecules or different pathways or their use in combination with other therapy methods make them ideal tools for the therapeutics field. It is worth noting that even with this excellent Nb performance, there is still no Nb-based product on the market. This fact may be caused by the very restrictive intellectual property policies and long, complicated, and expensive clinical trials together with the lack of making new technologies of paramount importance for new therapy strategies.
Outlook & Thanks to the major progress in the field of molecular biology and the emergence of many high-throughput technologies, together with their own physicochemical properties and reasonable price, Nbs are a real and advantageous alternative for diagnosis and therapy purposes. & Ag-induced active immunization is currently the most recommended strategy to produce high affinity Nbs. However, big steps are being accomplished to avoid animal treatment and to improve the affinity properties of Nbs using semisynthetic/synthetic libraries. However, still more rational and faster panning methods are needed to ensure the production of Nbs showing high affinity and selectivity. & The high stability of Nbs against high concentrations of organic solvents and extreme pHs and temperatures opens a wide range of applications for the detection of small molecules such as the development of more efficient methods of immobilization for biosensing purposes, the possibility to analyze pollutants at low concentrations after a preconcentration step (usually eluted using organic solvents), or the increase of the biorecognition kinetics by using high temperatures. & Incorporation of Nbs into different nanotechnology systems such as nanocarriers or biosensors will improve some of the drawbacks found in the currently raised Nbs such as the decrease of the renal clearance or the accomplishment of efficient refolding and functionalization of the transducer to get better affinity in terms of sensing. Moreover, Nbs can be encapsulated to improve even more their solubility, incorporating drugs or radiolabels for theranostics.
& Their Bready to use^potential places them as optimal imaging or therapeutic agents in the healthcare market. Different clinical trials are currently in progress prior to entry into the market. & Focusing on therapeutics, Nbs can overcome some of the limitations that first-generation Abs showed. Therefore, they are more efficient and do not seem to cause severe side effects. Although they have been successfully produced to treat patients with life-threatening diseases, the effects of Nbs need to be enhanced by increasing their effector properties in some cases and they are still designed to be administered in combination with other treatments.
